{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T22:30:06Z","timestamp":1764541806754},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research (ICMR), New Delhi","doi-asserted-by":"publisher","award":["53\/8\/2006-BMS"],"award-info":[{"award-number":["53\/8\/2006-BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ejphar.2015.08.034","type":"journal-article","created":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T01:33:53Z","timestamp":1440120833000},"page":"124-130","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"765","author":[{"given":"Shantashri","family":"Vaidya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanjaksha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrakala","family":"Shanmukhaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babu Rao","family":"Vundinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejphar.2015.08.034_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2015.08.034_bib2","first-page":"5015","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"5","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejphar.2015.08.034_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/leu.2010.86","article-title":"hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia","volume":"24","author":"Bazeos","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejphar.2015.08.034_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1179\/1607845412Y.0000000067","article-title":"Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?","volume":"18","author":"Bedewy","year":"2013","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.ejphar.2015.08.034_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000365437","article-title":"Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia","volume":"133","author":"Cao","year":"2015","journal-title":"Acta Haematol."},{"issue":"9","key":"10.1016\/j.ejphar.2015.08.034_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ejphar.2015.08.034_bib7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","article-title":"Metabolism considerations for kinase inhibitors in cancer treatment","volume":"6","author":"Duckett","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2015.08.034_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/bcmd.2002.0526","article-title":"Differences between in vivo and in vitro sensitivity to imatinib of Bcr\/Abl+ cells obtained from leukemic patients","volume":"28","author":"Gambacorti-Passerini","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2015.08.034_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib","volume":"80","author":"Gardner","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2015.08.034_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajh.21954","article-title":"Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies","volume":"86","author":"Gerrard","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.ejphar.2015.08.034_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","article-title":"The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukaemia","volume":"121","author":"Giannoudis","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejphar.2015.08.034_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.12591","article-title":"A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia","volume":"163","author":"Grinfeld","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.ejphar.2015.08.034_bib13","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2015.08.034_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"14","key":"10.1016\/j.ejphar.2015.08.034_bib15","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.ejphar.2015.08.034_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2015.08.034_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/ng1537","article-title":"Genome-wide strategies for detecting multiple loci that influence complex diseases","volume":"37","author":"Marchini","year":"2005","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.ejphar.2015.08.034_bib18","first-page":"39","article-title":"Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients","volume":"16","author":"Meng","year":"2011","journal-title":"Neurol. Asia"},{"issue":"3","key":"10.1016\/j.ejphar.2015.08.034_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2015.08.034_bib20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","article-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","volume":"20","author":"Nies","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ejphar.2015.08.034_bib21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejphar.2015.08.034_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00228-006-0105-3","article-title":"CYP3A phenotypes and genotypes in North Indians","volume":"62","author":"Rais","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.08.034_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00039-9","article-title":"Smart drugs: tyrosine kinase inhibitors in cancer therapy","volume":"1","author":"Shawver","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2015.08.034_bib24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"issue":"12","key":"10.1016\/j.ejphar.2015.08.034_bib25","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejphar.2015.08.034_bib26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejphar.2015.08.034_bib27","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1","volume":"24","author":"White","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejphar.2015.08.034_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10157-009-0215-1","article-title":"Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats","volume":"13","author":"Yokoo","year":"2009","journal-title":"Clin. Exp. Nephrol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915302089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915302089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T03:54:14Z","timestamp":1537415654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915302089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":28,"alternative-id":["S0014299915302089"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.034","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.08.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}